Pictet Asset Management Holding SA Purchases New Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Pictet Asset Management Holding SA acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 384,797 shares of the company’s stock, valued at approximately $20,602,000.

A number of other large investors have also recently made changes to their positions in JANX. Rhumbline Advisers increased its position in shares of Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after acquiring an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Janux Therapeutics by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after purchasing an additional 1,095 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Janux Therapeutics by 17.5% in the fourth quarter. Virtu Financial LLC now owns 8,769 shares of the company’s stock valued at $469,000 after purchasing an additional 1,306 shares in the last quarter. Avanza Fonder AB purchased a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $139,000. Finally, Zacks Investment Management grew its holdings in Janux Therapeutics by 8.7% during the third quarter. Zacks Investment Management now owns 42,133 shares of the company’s stock worth $1,914,000 after buying an additional 3,360 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the transaction, the chief executive officer now owns 293,054 shares of the company’s stock, valued at $17,583,240. This represents a 1.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,002 shares of company stock valued at $1,279,953 in the last quarter. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Stock Performance

JANX stock opened at $27.00 on Tuesday. The stock has a fifty day moving average of $35.33 and a 200-day moving average of $45.87. Janux Therapeutics, Inc. has a fifty-two week low of $26.40 and a fifty-two week high of $71.71. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -23.08 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

JANX has been the topic of several recent analyst reports. Wedbush restated an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. BTIG Research boosted their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $92.44.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.